Receptor-interacting serine-threonine kinase 3 Antibody
Rabbit Polyclonal IgG
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
Anti-Receptor-interacting serine-threonine kinase 3 antibody detects human RIP3. RIP3 is a novel member of RIP Ser/Thr kinase family. It is a potent inducer of apoptosis and is an important component of TNFR1 signaling complex. RIP3 consists of an N-terminal RIP-like-Kinase domain and a unique, non-homologous C-terminus responsible for caspase activation and apoptosis induction. RIP3 is expressed in multiple tissues including hematopoietic cells and plays a functional role in the regulation of apoptosis and NF-kB signaling. It is recruited to the TNFR1 signaling complex in a RIP-dependant manner where it induces apoptosis by activating caspases and/or inhibiting TNFR1-induced NF-kB activation. RIP3 negatively regulates the TLR3-Trif mediated NF-kB signaling pathway by competing with the binding of Trif to RIP1. The human RIP3 gene is localized in the chromosomal region 14q11.2. Anti-Receptor-interacting serine-threonine kinase 3 Antibody is ideal for investigators involved in apoptosis and NFkappaB research.
Product Details
Target Details
Application Details
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.